Amicus Therapeutics Inc.
Amicus Therapeutics Licenses DMX-200 from Dimerix for FSGS Treatment in the U.S.
Summary
Amicus Therapeutics, Inc. has entered into an exclusive license agreement with Dimerix Bioscience Pty Ltd. for the development, manufacture, and commercialization of DMX-200, a small molecule inhibitor of the chemokine receptor 2 (CCR2) for Focal Segmental Glomerulosclerosis (FSGS) and other indications in the United States. Dimerix will receive an upfront payment of $30 million, potential milestone payments up to $560 million, and royalties on net sales. Amicus will fund and execute the pivotal Phase 3 study for DMX-200 for FSGS, while Amicus will be responsible for regulatory submissions and commercialization in the U.S. Amicus will also have the exclusive rights to develop DMX-200 in other future indications in the United States.
Profitelligence Alerts
Get alerts for FOLD
Be first to know when Amicus Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Amicus Therapeutics Inc.
Amicus Therapeutics Inc. is a biopharmaceutical company dedicated to developing advanced therapies for rare and orphan diseases. Its primary focus is on genetic disorders, particularly lysosomal storage disorders and other diseases resulting from improper protein folding within cells. Amicus leverages its proprietary technology platforms to create drug candidates that address unmet medical needs, providing innovative solutions for complex conditions like Fabry disease and Pompe disease. The company's commitment to patient-centric innovation aims to enhance the quality of life for individuals facing challenging health diagnoses. Situated within the biotechnology sector, Amicus plays a significant role in advancing novel treatment options, thereby impacting healthcare markets and potentially transforming the standard of care for rare genetic diseases. Founded in 2002, the company harnesses cutting-edge research and collaborations to foster groundbreaking developments in the therapeutic landscape uniquely shaped by the complexities of rare diseases.
Official SEC Documents
Advertisement